Cybin Inc. Receives EU Approval for Phase 3 MDD Study of CYB003

Cybin Inc., a clinical-stage neuropsychiatry company, has announced the European approval to initiate its EMBRACE Phase 3 study in Ireland, Poland, and Greece. This study is a critical component of the company's PARADIGM program, which evaluates CYB003, a proprietary deuterated psilocin analog that has been granted Breakthrough Therapy Designation by the FDA for Major Depressive Disorder (MDD). The EMBRACE study aims to enroll 330 participants across multiple international sites, focusing on individuals with inadequately controlled MDD symptoms. It will assess the efficacy of two CYB003 dose levels against a placebo, offering hope for a new treatment option in the mental health sector.

The approval to launch the EMBRACE study in Europe represents a significant milestone for Cybin Inc. and the field of neuropsychiatry. MDD affects millions worldwide, and current treatments often fall short in providing long-lasting relief for many patients. CYB003's unique mechanism of action and its designation as a Breakthrough Therapy underscore its potential to address the unmet needs in MDD treatment. The study's outcomes could pave the way for innovative, intermittent treatments that offer sustained benefits, revolutionizing the approach to mental health care.

For more details on Cybin Inc.'s groundbreaking work and the EMBRACE study, visit https://ibn.fm/TnWsD. This development not only highlights Cybin's commitment to advancing mental health treatments but also signals a promising direction for patients and healthcare providers seeking effective solutions for MDD.